fda indications for semaglutide Semaglutide- weight loss in obesity What if you could get

This piece explains how to convert dosages between milligrams and unitsa key difference between brands like Ozempic and Wegovy

Meet our doctors Last reviewed: 02 Jun 2026 Sources A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) (STEP UP), Diabetes & endocrinology [accessed 26 September 2025] MHRA approves GLP1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults, GOV.UK [accessed 26 September 2025] Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval, Reuters [accessed 26 September 2025] Once-weekly semaglutide 72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial, The Lancet [accessed 26 September 2025] Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen (PIL), emc [accessed 26 September 2025]

The relatively short study duration of 30 weeks also warrants longer-term future studies to confirm the current findings

Putting Semaglutide To The Test Scientists used a method called target trial emulation to pit semaglutide against seven other diabetes medications